Recent 8-K filings for RNXT

• May 14, 2026, 4:17 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  RenovoRx Q1 revenue $563K (+136% QoQ); net loss $3.5M; reaffirms FY revenue guidance $3-4M

  Revenue $563,000, up 136% from Q4 2025; exceeds 50% of total FY2025 revenue.

• March 30, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 8.01item 9.01 ◈ Earnings Releases

  RenovoRx reports 2025 revenue of $1.1M from RenovoCath; net loss $11.2M; cash $13M after $10M financing

  FY2025 revenue $1.1M vs $43K in 2024; first full year of RenovoCath commercialization; cost of revenue $327K, gross profit $796K.

• March 27, 2026, 7:59 PM ET leadership materiality 0.45 positive item 5.02item 9.01

  RenovoRx appoints Ramtin Agah, MD as Executive Chairman; $450K salary + bonus

  Ramtin Agah, MD appointed Executive Chairman effective Feb 27, 2026; continues as Chief Medical Officer.

• March 23, 2026, 7:59 PM ET other material materiality 0.70 positive item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements

  RenovoRx raises $10M via common stock and milestone warrants in oversubscribed offering

  Raised ~$10M gross from sale of 8.4M shares, 2.2M pre-funded warrants, and 5.3M milestone warrants to 15 investors (including insiders).

• February 6, 2026, 6:59 PM ET leadership materiality 0.60 positive item 5.02item 8.01item 9.01

  RenovoRx appoints Mark Voll as CFO; Kocak resigns as Principal Accounting Officer but remains Controller

  Mark Voll, age 72, appointed CFO effective Feb 4, 2026; also serves as Principal Financial and Accounting Officer.

• January 2, 2026, 6:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  RenovoRx receives Nasdaq deficiency notice for minimum bid price non-compliance

  Received Nasdaq notice Dec 31, 2025; closing bid price below $1.00 for 32 consecutive business days.

• November 14, 2025, 6:59 PM ET other material materiality 0.50 neutral item 1.01item 9.01

  RenovoRx enters $3.7M ATM equity sales agreement with JonesTrading

  Up to $3,723,029 in common stock may be sold at-the-market through JonesTrading; 3.0% commission.

• November 13, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 8.01item 9.01

  RenovoRx reports Q3 revenue $266K, net loss $2.9M; expands to 14 approved cancer centers

  Q3 revenue $266K from RenovoCath sales; year-to-date revenue ~$900K from zero prior year.

• August 14, 2025, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 8.01item 9.01

  RenovoRx Q2 2025 revenue $422k from RenovoCath; DMC recommends continue Phase III trial

  Q2 2025 revenue $422k from commercial RenovoCath sales, up from $0 in Q2 2024.

• June 25, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  RenovoRx shareholders elect directors, approve equity plan amendment, ratify auditor

  All six director nominees elected; three directors received >3.2M withheld votes each.

• May 15, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 8.01item 9.01

  RenovoRx Q1 revenue ~$200K from RenovoCath sales; TIGeR-PaC trial 91 patients randomized

  Q1 2025 revenue of ~$200K from commercial RenovoCath sales, exceeding internal expectations; gross profit $103K.

• April 1, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 8.01item 9.01

  RenovoRx reports first RenovoCath revenue of $43k in Q4 2024; TIGeR-PaC trial 79% enrolled

  First commercial RenovoCath revenue ~$43k in Q4 2024; sequential growth expected in 2025.

• February 10, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01

  RenovoRx prices $12.1M underwritten public offering of 11.5M shares at $1.05 per share

  Offering of 11,523,810 shares at $1.05/share; gross proceeds ~$12.1M, net ~$10.9M after underwriting discounts and expenses.

• November 14, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  RenovoRx Q3 2024 net loss $2.5M; cash $9.6M, trial interim analysis targeted late 2024/early 2025

  Net loss of $2.5M in Q3 2024 vs $1.4M loss in Q3 2023; R&D flat at $1.7M, G&A down to $1.2M.

• September 25, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  RenovoRx increases RenovoCath production, expands Medical Murray partnership with warrant for 709,500 shares

  RenovoRx boosts production of FDA-cleared RenovoCath catheter due to strong physician demand; over 500 procedures performed.

• August 16, 2024, 7:59 PM ET other materiality 0.20 neutral item 4.01

  RenovoRx appoints Frank Rimerman as auditor effective Aug 12, 2024

  Baker Tilly resigned effective Aug 13, 2024 after filing Q2 10-Q.

• June 7, 2024, 7:59 PM ET other material materiality 0.40 neutral item 5.02item 5.07item 9.01

  RenovoRx enters severance deal with VP/Controller Kocak; annual meeting re-elects six directors

  Severance provides 50% of base salary on qualifying termination; 100% plus full equity vesting if within 12 months of a change in control.

• May 3, 2024, 7:59 PM ET other material materiality 0.60 neutral item 4.01item 5.02item 9.01 ◈ Auditor Changes

  RenovoRx auditor Baker Tilly to resign; CEO salary restored with bonuses after $17.2M equity raise

  Baker Tilly resigns as auditor effective after Q2 2024 10-Q filing (expected Aug 2024); no accounting disagreements.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.60 · Most common event earnings

9 positive 1 negative 8 neutral

source · RNXT on sec.gov